Yazar "Koca, Sebile" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Yayın
    Decreased levels of cytokines implicate altered immune response in plasma of moderate-stage Alzheimer’s disease patients
    (Elsevier, 2022) Koca, Sebile; Kiriş, İrem; Şahin, Şevki; Çınar, Nilgün; Karşıdağ, Sibel; Hanagasi, Haşmet A.; Yıldız, Gülsen B.; Baykal, Ahmet Tarık
    Alzheimer’s Disease (AD) is a neurodegenerative disease characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. However, increasing evidence suggests that the pathogenesis of the disease is associated with peripheral inflammation. Here, we aimed to determine plasma concentrations of multiple cytokines and chemokines from moderate-stage AD and age-matched controls. Changes in a total of 20 cytokines and chemokines in plasma of moderate-stage AD were evaluated by using quantitative microarray. Six of them, namely MCP-1, MIP-1a, MIP-1b, MMP-9, RANTES, and VEGF, were found to be significantly reduced in moderate-stage AD patients (n = 25) in comparison to age-matched and non-demented controls (n = 25). However, GM-CSF, GRO-?/?/?, IFN- ?, IL-1?, IL-1?, IL-10, IL-12 p70, IL-13, IL-2, IL- 4, IL-5, IL-6, IL-8, and TNF-? showed no significant differences between the patient and control groups. On the contrary to previous early-stage AD studies that show increased plasma cytokine/chemokine levels, our results indicate that inflammatory plasma molecules are reduced in moderate-stage AD. This finding points out the reduced immune responsiveness, which is known to be directly correlated to the degree of AD.
  • Küçük Resim Yok
    Yayın
    Kappa/Lambda Light-chain Typing in Alzheimer's Disease
    (Bentham Science Publ Ltd, 2022) Kaya, Zelal Zuhal; Tuzuner, Mete Bora; Şahin, Betul; Akgün, Emel; Aksungar, Fehime; Koca, Sebile; Serdar, Muhittin
    Background: Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss and cognitive impairment. The diagnosis of Alzheimer's disease according to symptomatic events is still a puzzling task. Developing a biomarker-based, low-cost, and high-throughput test, readily applicable in clinical laboratories, dramatically impacts the rapid and reliable detection of the disease. Objective: This study aimed to develop an accurate, sensitive, and reliable screening tool for diagnosing Alzheimer's disease, which can significantly reduce the cost and time of existing methods. Methods: We have employed a MALDI-TOF-MS-based methodology combined with a microaffinity chromatography enrichment approach using affinity capture resins to determine serum kappa (kappa) and lambda (lambda) light chain levels in control and patients with AD. Results: We observed a statistically significant difference in the kappa light chain over lambda light chain (kappa LC/lambda LC) ratios between patients with AD and controls (mean difference -0,409; % 95 CI: -0.547 to -0.269; p<0.001). Our method demonstrated higher sensitivity (100.00%) and specificity (71.43%) for discrimination between AD and controls. Conclusion: We have developed a high-throughput screening test with a novel sample enrichment method for determining kappa LC/kappa LC ratios associated with AD diagnosis. Following further validation, we believe our test has the potential for clinical laboratories.